Search

Your search keyword '"Barbolini, M"' showing total 66 results
Start Over Author "Barbolini, M" Publication Year Range Last 10 years
66 results on '"Barbolini, M"'

3. Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Author

Omarini C, Palumbo P, Pecchi A, Draisci S, Balduzzi S, Nasso C, Barbolini M, Isca C, Bocconi A, Moscetti L, Galetti S, Tazzioli G, Torricelli P, Cascinu S, and Piacentini F

Subjects
bmi, fat tissue, sarcopenia, pathological complete response, breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Claudia Omarini,1 Patrizia Palumbo,2 Annarita Pecchi,3 Stefano Draisci,3 Sara Balduzzi,4 Cecilia Nasso,1 Monica Barbolini,1 Chrystel Isca,1 Alessandro Bocconi,1 Luca Moscetti,1 Silvia Galetti,5 Giovanni Tazzioli,6 Pietro Torricelli,3 Stefano Cascinu,1 Federico Piacentini1 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 2Division of Clinical Nutrition and Metabolism, Department of Specialist Medicines, University Hospital of Modena, Modena, Italy; 3Department of Radiology, University Hospital of Modena, Modena, Italy; 4Statistics Unit, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 5Division of Clinical Nutrition and Metabolism, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 6Department of General Surgery and Surgical Specialities, University Hospital of Modena, Modena, ItalyCorrespondence: Claudia OmariniDivision of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Via Del Pozzo 71, Modena 41122, ItalyTel +39 059 4222845Email claudia.omarini@gmail.comBackground: Fat tissue is strongly involved in BC tumorigenesis inducing insulin resistance, chronic inflammation and hormonal changes. Computed tomography (CT) imaging instead of body mass index (BMI) gives a reliable measure of skeletal muscle mass and body fat distribution. The impact of body composition parameters (BCPs) on chemosensitivity is still debated. We examined the associations between BCPs and tumor response to neoadjuvant chemotherapy (NC) in patients treated for operable breast cancer (BC).Methods: A retrospective review of BC patients treated with NC in Modena Cancer Center between 2005 and 2017 was performed. BCPs, such as subcutaneous fat area (SFA), visceral fat area (VFA), lumbar skeletal muscle index (LSMI) and liver-to-spleen (L/S) ratio were calculated by Advance workstation (General Electric), software ADW server 3.2 or 4.7. BMI and BCPs were correlated with pathological complete response (pCR) and survival outcomes.Results: 407 patients were included in the study: 55% with BMI < 25 and 45% with BMI ≥ 25. 137 of them had pre-treatment CT scan imagines. Overweight was significantly associated with postmenopausal status and older age. Hormonal receptor positive BC was more frequent in overweight patients (p

Published
2019

4. P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial

Author

Canino, F., primary, Barbolini, M., additional, De Giorgi, U., additional, Dominici, M., additional, Gianni, L., additional, Moscetti, L., additional, Omarini, C., additional, Zamagni, C., additional, Molinaro, A., additional, Antonelli, G., additional, Baglio, F., additional, Martinelli, G., additional, Natalizio, S., additional, Ponzoni, O., additional, and Piacentini, F., additional

Published
2023
Full Text
View/download PDF

10. The Italian reference sites of the European innovation partnership on active and healthy ageing: Progetto Mattone Internazionale as an enabling factor

Author

Illario M., De Luca V., Tramontano G., Menditto E., Iaccarino G., Bertorello L., Palummeri E., Romano V., Moda G., Maggio M., Barbolini M., Leonardini L., Addis A., Illario, M., De Luca, V., Tramontano, G., Menditto, E., Iaccarino, G., Bertorello, L., Palummeri, E., Romano, V., Moda, G., Maggio, M., Barbolini, M., Leonardini, L., and Addis, A.

Subjects
Aged, 80 and over, Ageing, European collaboration, Aging, Italy, Health, Population, EIP-AHA reference site, European Union, Aged, Government Agencie, Human
Published
2017

12. Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials

Author

Omarini, C., primary, Sperduti, I., additional, Barbolini, M., additional, Isca, C., additional, Bocconi, A., additional, Toss, A., additional, Cortesi, L., additional, Barbieri, E., additional, Piacentini, F., additional, Cascinu, S., additional, and Moscetti, L., additional

Published
2019
Full Text
View/download PDF

13. A NOVEL TOOL FOR THE EARLY IDENTIFICATION OF FRAILTY IN ELDERLY PEOPLE: THE APPLICATION IN PRIMARY CARE SETTINGS

Author

Maggio, M., primary, Barbolini, M., additional, Longobucco, Y., additional, Barbieri, L., additional, Benedetti, C., additional, Bono, F., additional, Cacciapuoti, I., additional, Donatini, A., additional, Iezzi, E., additional, Papini, D., additional, Rodelli, P.M., additional, Tagliaferri, S., additional, and Moro, M.L., additional

Published
2019
Full Text
View/download PDF

14. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: A SUNFRAIL report

Author

Bousquet, J. Onorato, G.L. Bachert, C. Barbolini, M. Bedbrook, A. Bjermer, L. De Sousa, J.C. Chavannes, N.H. Cruz, A.A. De Manuel Keenoy, E. Devillier, P. Fonseca, J. Hun, S. Kostka, T. Hellings, P.W. Illario, M. Ivancevich, J.C. Larenas-Linnemann, D. Millot-Keurinck, J. Ryan, D. Samolinski, B. Sheikh, A. Yorgancioglu, A. Agache, I. Arnavielhe, S. Bewick, M. Annesi-Maesano, I. Anto, J.M. Bergmann, K.C. Bindslev-Jensen, C. Bosnic-Anticevich, S. Bouchard, J. Caimmi, D.P. Camargos, P. Canonica, G.W. Cardona, V. Carriazo, A.M. Cingi, C. Colgan, E. Custovic, A. Dahl, R. Demoly, P. De Vries, G. Fokkens, W.J. Fontaine, J.F. Gemicioǧlu, B. Guldemond, N. Gutter, Z. Haahtela, T. Hellqvist-Dahl, B. Jares, E. Joos, G. Just, J. Khaltaev, N. Keil, T. Klimek, L. Kowalski, M.L. Kull, I. Kuna, P. Kvedariene, V. Laune, D. Louis, R. Magnan, A. Malva, J. Mathieu-Dupas, E. Melén, E. Menditto, E. Morais-Almeida, M. Mösges, R. Mullol, J. Murray, R. Neffen, H. O'Hehir, R. Palkonen, S. Papadopoulos, N.G. Passalacqua, G. Pépin, J.L. Portejoie, F. Price, D. Pugin, B. Raciborski, F. Simons, F.E.R. Sova, M. Spranger, O. Stellato, C. Todo Bom, A. Tomazic, P.V. Triggiani, M. Valero, A. Valovirta, E. Vandenplas, O. Valiulis, A. Van Eerd, M. Ventura, M.T. Wickman, M. Young, I. Zuberbier, T. Zurkuhlen, A. Senn, A.

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices. © 2017 The Author(s).

Published
2017

15. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: A SUNFRAIL report

Author

Bousquet, J. and Onorato, G.L. and Bachert, C. and Barbolini, M. and Bedbrook, A. and Bjermer, L. and De Sousa, J.C. and Chavannes, N.H. and Cruz, A.A. and De Manuel Keenoy, E. and Devillier, P. and Fonseca, J. and Hun, S. and Kostka, T. and Hellings, P.W. and Illario, M. and Ivancevich, J.C. and Larenas-Linnemann, D. and Millot-Keurinck, J. and Ryan, D. and Samolinski, B. and Sheikh, A. and Yorgancioglu, A. and Agache, I. and Arnavielhe, S. and Bewick, M. and Annesi-Maesano, I. and Anto, J.M. and Bergmann, K.C. and Bindslev-Jensen, C. and Bosnic-Anticevich, S. and Bouchard, J. and Caimmi, D.P. and Camargos, P. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Cingi, C. and Colgan, E. and Custovic, A. and Dahl, R. and Demoly, P. and De Vries, G. and Fokkens, W.J. and Fontaine, J.F. and Gemicioǧlu, B. and Guldemond, N. and Gutter, Z. and Haahtela, T. and Hellqvist-Dahl, B. and Jares, E. and Joos, G. and Just, J. and Khaltaev, N. and Keil, T. and Klimek, L. and Kowalski, M.L. and Kull, I. and Kuna, P. and Kvedariene, V. and Laune, D. and Louis, R. and Magnan, A. and Malva, J. and Mathieu-Dupas, E. and Melén, E. and Menditto, E. and Morais-Almeida, M. and Mösges, R. and Mullol, J. and Murray, R. and Neffen, H. and O'Hehir, R. and Palkonen, S. and Papadopoulos, N.G. and Passalacqua, G. and Pépin, J.L. and Portejoie, F. and Price, D. and Pugin, B. and Raciborski, F. and Simons, F.E.R. and Sova, M. and Spranger, O. and Stellato, C. and Todo Bom, A. and Tomazic, P.V. and Triggiani, M. and Valero, A. and Valovirta, E. and Vandenplas, O. and Valiulis, A. and Van Eerd, M. and Ventura, M.T. and Wickman, M. and Young, I. and Zuberbier, T. and Zurkuhlen, A. and Senn, A., Contre les MAladies Chroniques Pour un VIeillissement, Actif en France Europ. Innov. Partnership on Active and Healthy Ageing Ref. Site, Montpellier, France, INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Regione Emilia Romagna - Agenzia Sanitaria e Sociale, Reference Site of the European Innovation Partnership on Healthy and Active Ageing, Bologna, Italy, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, GARD Executive Committee, Salvador, Brazil, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bilbao Bizkaia, Spain, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Versailles, France, Center for Health Technology and Services Research- CINTESIS, Faculdade de Medicina, Universidade Do Porto, Porto, Portugal, Allergy Unit, CUF Porto Instituto and Hospital, Porto, Portugal, Public Health Agency Northern Ireland, Belfast, United Kingdom, Department of Geriatrics, Medical University of Lodz, Healthy Ageing Research Centre (HARC), Lodz, Poland, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium, Division for Health Innovation, Campania Region, Federico II University Hospital Naples, RandD and DISMET, Naples, Italy, Allergy and Immunology Department, Santa Isabel, Buenos Aires, Argentina, Clínica de Alergia, Asma y Pediatría, Hospital Médica sur, Mexico, Mexico, Caisse Assurance Retraite et Santé Au Travail Languedoc-Roussillon (CARSAT-LR), Montpellier, 34000, France, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Pulmonology, Celal Bayar University, Manisa, Turkey, GARD Executive Committee, Manisa, Turkey, Faculty of Medicine, Transylvania University, Brasov, Romania, Kyomed, Montpellier, France, IQ4U Consultants Ltd, London, United Kingdom, EPAR U707 INSERM, Paris and EPAR UMR-S UPMC, Paris VI, Paris, France, Centre for Research in Environmental Epidemiology (CREAL), ISGLoBAL, Barcelona, Spain, IMIM, Hospital Del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Laval's University, Quebec City, Canada, Hôpital de la Malbaie, Quebec City, Canada, CHRU de Montpellier, Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris, 75013, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano Milan, Italy, Allergologia, S Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, Department of Pediatric, Imperial College London, London, United Kingdom, Peercode DV, Gerdermalsen, Netherlands, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Allergist, Reims, France, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Institute of Health Policy and Management IBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc, National EHealth Centre, Olomouc, Czech Republic, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark, Libra Foundation, Buenos Aires, Argentina, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France, UPMC Univ Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, Paris, 75013, France, GARD, Geneva, Switzerland, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology Rheumatology and Allergy, Medical University of Lodz, HARC, Lodz, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet Stockholm, Stockholm, Sweden, Division of Internal Medicine Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Clinic of Infectious Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium, Service de Pneumologie, UMR INSERM, UMR1087 and CNR 6291, L'Institut du Thorax, University of Nantes, Nantes, France, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, CIRFF, Federico II University, Naples, Italy, Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisbon, Portugal, Institute of Medical Statistics, Informatics and Epidemiology, Medical Faculty, University of Cologne, Cologne, Germany, Clinical and Experimental Respiratory Immunoallergy, ENT Department, Hospital Clínic, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Spain, Medical Communications Consultant, MedScript Ltd, Dundalk Co Louth, Ireland, Argentina Center for Allergy and Immunology, Alassia Children's Hospital, Santa Fe, Santa Fe, Argentina, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, M13 9WL, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital PandA Kyriakou, University of Athens, Athens, 11527, Greece, Allergy and Respiratory Diseases, IRCCS San Martino Hospital, IST-University of Genoa, Genoa, Italy, CHU Grenoble, La Tronche, France, Observational and Pragmatic Research Institute, Singapore, Singapore, Optimum Patient Care, Cambridge, United Kingdom, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, University Hospital Olomouc, Olomouc, Czech Republic, Global Allergy and Asthma Platform GAAPP, Altgasse 8-10, Vienna, 1130, Austria, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Queen's University Belfast, Belfast, United Kingdom, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, EC-CNECT-H2, European Commission, Brussels, Belgium, and CHU Montpellier, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, 34295, France

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices. © 2017 The Author(s).

Published
2017

18. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J, Onorato, G L, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, J Correia, Chavannes, N H, Cruz, A A, De Manuel Keenoy, E, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, P W, Illario, M, Ivancevich, J C, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A, Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, J M, Bergmann, K C, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, G W, Cardona, V, Carriazo, A M, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, De Vries, G, Fokkens, W J, Fontaine, J F, Gemicioğlu, B, Guldemond, N, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, M L, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melén, E, Menditto, E, Morais-Almeida, M, Mösges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, N G, Passalacqua, G, Pépin, J L, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, F E R, Sova, M, Spranger, O, Stellato, C, Todo Bom, A, Tomazic, P V, Triggiani, M, Valero, A, Valovirta, E, VandenPlas, Olivier, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, Senn, A, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J, Onorato, G L, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, J Correia, Chavannes, N H, Cruz, A A, De Manuel Keenoy, E, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, P W, Illario, M, Ivancevich, J C, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A, Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, J M, Bergmann, K C, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, G W, Cardona, V, Carriazo, A M, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, De Vries, G, Fokkens, W J, Fontaine, J F, Gemicioğlu, B, Guldemond, N, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, M L, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melén, E, Menditto, E, Morais-Almeida, M, Mösges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, N G, Passalacqua, G, Pépin, J L, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, F E R, Sova, M, Spranger, O, Stellato, C, Todo Bom, A, Tomazic, P V, Triggiani, M, Valero, A, Valovirta, E, VandenPlas, Olivier, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, and Senn, A

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.

Published
2017

19. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

Bousquet, J. (Jean), Onorato, G.L., Bachert, C. (Claus), Barbolini, M., Bedbrook, A. (Anna), Bjermer, L. (Leif), de Sousa, JC, Chavannes, N.H. (Nicolas), Cruz, A.A. (Alvaro), Keenoy, ED, Devillier, P. (Philippe), Fonseca, J, Hun, S., Kostka, T., Hellings, P.W. (Peter), Illario, M., Ivancevich, J.C. (Juan), Larenas-Linnemann, D. (Désirée), Millot-Keurinck, J., Ryan, D. (Dermot), Samolinski, B. (Boleslaw), Sheikh, A. (Aziz), Yorgancioglu, A., Agache, I., Arnavielhe, S, Bewick, M, Annesi-Maesano, I. (Isabella), Anto, JM, Bergmann, K.-C. (Karl-Christian), Bindslev-Jensen, C. (Carsten), Bosnic-Anticevich, S, Bouchard, J. (Jacques), Caimmi, D. P., Camargos, P., Canonica, G.W., Cardona, V, Carriazo, A.M., Cingi, C., Colgan, E., Custovic, A. (Adnan), Dahl, R., Demoly, P., Vries, G. (Gerard) de, Fokkens, WJ, Fontaine, J.F., Gemicioglu, B, Guldemond, N. (Nick), Gutter, Z., Haahtela, T. (Tari), Hellqvist-Dahl, B., Jares, E., Joos, G.F. (Guy), Just, P.M., Khaltaev, N., Keil, M. (Mark), Klimek, L., Kowalski, M.L., Kull, C.A. (Christian), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Laune, D, Louis, R, Magnan, A, Malva, J., Mathieu-Dupas, E., Melén, E. (Erik), Menditto, E., Morais-Almeida, M. (Mario), Mosges, R, Mullol, J., Murray, R., Neffen, H, O'Hehir, R, Palkonen, S., Papadopoulos, N., Passalacqua, G. (Giovanni), Pepin, J.L., Portejoie, F, Price, D., Pugin, B., Raciborski, F, Simons, F.E.R., Sova, M., Spranger, O., Stellato, C., Bom, AT, Tomazic, P.V., Triggiani, M. (M.), Valero, A., Valovirta, E. (Erkka), Vandenplas, O. (Olivier), Valiulis, A. (Arunas), Eerd, M. (Maarten) van, Ventura, M. T., Wickman, M., Young, I, Zuberbier, T. (Torsten), Zurkuhlen, A., Senn, A., Bousquet, J. (Jean), Onorato, G.L., Bachert, C. (Claus), Barbolini, M., Bedbrook, A. (Anna), Bjermer, L. (Leif), de Sousa, JC, Chavannes, N.H. (Nicolas), Cruz, A.A. (Alvaro), Keenoy, ED, Devillier, P. (Philippe), Fonseca, J, Hun, S., Kostka, T., Hellings, P.W. (Peter), Illario, M., Ivancevich, J.C. (Juan), Larenas-Linnemann, D. (Désirée), Millot-Keurinck, J., Ryan, D. (Dermot), Samolinski, B. (Boleslaw), Sheikh, A. (Aziz), Yorgancioglu, A., Agache, I., Arnavielhe, S, Bewick, M, Annesi-Maesano, I. (Isabella), Anto, JM, Bergmann, K.-C. (Karl-Christian), Bindslev-Jensen, C. (Carsten), Bosnic-Anticevich, S, Bouchard, J. (Jacques), Caimmi, D. P., Camargos, P., Canonica, G.W., Cardona, V, Carriazo, A.M., Cingi, C., Colgan, E., Custovic, A. (Adnan), Dahl, R., Demoly, P., Vries, G. (Gerard) de, Fokkens, WJ, Fontaine, J.F., Gemicioglu, B, Guldemond, N. (Nick), Gutter, Z., Haahtela, T. (Tari), Hellqvist-Dahl, B., Jares, E., Joos, G.F. (Guy), Just, P.M., Khaltaev, N., Keil, M. (Mark), Klimek, L., Kowalski, M.L., Kull, C.A. (Christian), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Laune, D, Louis, R, Magnan, A, Malva, J., Mathieu-Dupas, E., Melén, E. (Erik), Menditto, E., Morais-Almeida, M. (Mario), Mosges, R, Mullol, J., Murray, R., Neffen, H, O'Hehir, R, Palkonen, S., Papadopoulos, N., Passalacqua, G. (Giovanni), Pepin, J.L., Portejoie, F, Price, D., Pugin, B., Raciborski, F, Simons, F.E.R., Sova, M., Spranger, O., Stellato, C., Bom, AT, Tomazic, P.V., Triggiani, M. (M.), Valero, A., Valovirta, E. (Erkka), Vandenplas, O. (Olivier), Valiulis, A. (Arunas), Eerd, M. (Maarten) van, Ventura, M. T., Wickman, M., Young, I, Zuberbier, T. (Torsten), Zurkuhlen, A., and Senn, A.

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life da

Published
2017
Full Text
View/download PDF

20. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

Bousquet, J., Onorato, G. L., Bachert, C., Barbolini, M., Bedbrook, A., Bjermer, L., de Sousa, J. Correia, Chavannes, N. H., Cruz, A. A., Keenoy, E. De Manuel, Devillier, P., Fonseca, J., Hun, S., Kostka, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Larenas-Linnemann, D., Millot-Keurinck, J., Ryan, D., Samolinski, B., Sheikh, A., Yorgancioglu, A., Agache, I., Arnavielhe, S., Bewick, M., Annesi-Maesano, I., Anto, J. M., Bergmann, K. C., Bindslev-Jensen, C., Bosnic-Anticevich, S., Bouchard, J., Caimmi, D. P., Camargos, P., Canonica, G. W., Cardona, V., Carriazo, A. M., Cingi, C., Colgan, E., Custovic, A., Dahl, R., Demoly, P., De Vries, G., Fokkens, W. J., Fontaine, J. F., Gemicioglu, B., Guldemond, N., Gutter, Z., Haahtela, T., Hellqvist-Dahl, B., Jares, E., Joos, G., Just, J., Khaltaev, N., Keil, T., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Laune, D., Louis, R., Magnan, A., Malva, J., Mathieu-Dupas, E., Melen, E., Menditto, E., Morais-Almeida, M., Mosges, R., Mullol, J., Murray, R., Neffen, H., O'Hehir, R., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pepin, J. L., Portejoie, F., Price, D., Pugin, B., Raciborski, F., Simons, F. E. R., Sova, M., Spranger, O., Stellato, C., Bom, A. Todo, Tomazic, P. V., Triggiani, M., Valero, A., Valovirta, E., VandenPlas, O., Valiulis, A., Van Eerd, M., Ventura, M. T., Wickman, M., Young, I., Zuberbier, T., Zurkuhlen, A., Senn, A., Bousquet, J., Onorato, G. L., Bachert, C., Barbolini, M., Bedbrook, A., Bjermer, L., de Sousa, J. Correia, Chavannes, N. H., Cruz, A. A., Keenoy, E. De Manuel, Devillier, P., Fonseca, J., Hun, S., Kostka, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Larenas-Linnemann, D., Millot-Keurinck, J., Ryan, D., Samolinski, B., Sheikh, A., Yorgancioglu, A., Agache, I., Arnavielhe, S., Bewick, M., Annesi-Maesano, I., Anto, J. M., Bergmann, K. C., Bindslev-Jensen, C., Bosnic-Anticevich, S., Bouchard, J., Caimmi, D. P., Camargos, P., Canonica, G. W., Cardona, V., Carriazo, A. M., Cingi, C., Colgan, E., Custovic, A., Dahl, R., Demoly, P., De Vries, G., Fokkens, W. J., Fontaine, J. F., Gemicioglu, B., Guldemond, N., Gutter, Z., Haahtela, T., Hellqvist-Dahl, B., Jares, E., Joos, G., Just, J., Khaltaev, N., Keil, T., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Laune, D., Louis, R., Magnan, A., Malva, J., Mathieu-Dupas, E., Melen, E., Menditto, E., Morais-Almeida, M., Mosges, R., Mullol, J., Murray, R., Neffen, H., O'Hehir, R., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pepin, J. L., Portejoie, F., Price, D., Pugin, B., Raciborski, F., Simons, F. E. R., Sova, M., Spranger, O., Stellato, C., Bom, A. Todo, Tomazic, P. V., Triggiani, M., Valero, A., Valovirta, E., VandenPlas, O., Valiulis, A., Van Eerd, M., Ventura, M. T., Wickman, M., Young, I., Zuberbier, T., Zurkuhlen, A., and Senn, A.

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.

Published
2017

21. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, Senn, A, Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, and Senn, A

Published
2017

23. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

Bousquet, J., primary, Onorato, G. L., additional, Bachert, C., additional, Barbolini, M., additional, Bedbrook, A., additional, Bjermer, L., additional, de Sousa, J. Correia, additional, Chavannes, N. H., additional, Cruz, A. A., additional, De Manuel Keenoy, E., additional, Devillier, P., additional, Fonseca, J., additional, Hun, S., additional, Kostka, T., additional, Hellings, P. W., additional, Illario, M., additional, Ivancevich, J. C., additional, Larenas-Linnemann, D., additional, Millot-Keurinck, J., additional, Ryan, D., additional, Samolinski, B., additional, Sheikh, A., additional, Yorgancioglu, A., additional, Agache, I., additional, Arnavielhe, S., additional, Bewick, M., additional, Annesi-Maesano, I., additional, Anto, J. M., additional, Bergmann, K. C., additional, Bindslev-Jensen, C., additional, Bosnic-Anticevich, S., additional, Bouchard, J., additional, Caimmi, D. P., additional, Camargos, P., additional, Canonica, G. W., additional, Cardona, V., additional, Carriazo, A. M., additional, Cingi, C., additional, Colgan, E., additional, Custovic, A., additional, Dahl, R., additional, Demoly, P., additional, De Vries, G., additional, Fokkens, W. J., additional, Fontaine, J. F., additional, Gemicioğlu, B., additional, Guldemond, N., additional, Gutter, Z., additional, Haahtela, T., additional, Hellqvist-Dahl, B., additional, Jares, E., additional, Joos, G., additional, Just, J., additional, Khaltaev, N., additional, Keil, T., additional, Klimek, L., additional, Kowalski, M. L., additional, Kull, I., additional, Kuna, P., additional, Kvedariene, V., additional, Laune, D., additional, Louis, R., additional, Magnan, A., additional, Malva, J., additional, Mathieu-Dupas, E., additional, Melén, E., additional, Menditto, E., additional, Morais-Almeida, M., additional, Mösges, R., additional, Mullol, J., additional, Murray, R., additional, Neffen, H., additional, O’Hehir, R., additional, Palkonen, S., additional, Papadopoulos, N. G., additional, Passalacqua, G., additional, Pépin, J. L., additional, Portejoie, F., additional, Price, D., additional, Pugin, B., additional, Raciborski, F., additional, Simons, F. E. R., additional, Sova, M., additional, Spranger, O., additional, Stellato, C., additional, Todo Bom, A., additional, Tomazic, P. V., additional, Triggiani, M., additional, Valero, A., additional, Valovirta, E., additional, VandenPlas, O., additional, Valiulis, A., additional, van Eerd, M., additional, Ventura, M. T., additional, Wickman, M., additional, Young, I., additional, Zuberbier, T., additional, Zurkuhlen, A., additional, and Senn, A., additional

Published
2017
Full Text
View/download PDF

26. Soluble TRAIL-Armed Human AD-MSC as Novel Cell Therapy

Author

Spano, C., primary, Grisendi, G., additional, Candini, O., additional, Golinelli, G., additional, Petrachi, T., additional, Rossignoli, F., additional, Prapa, M., additional, Orsi, G., additional, Barbolini, M., additional, Rovesti, G., additional, Maiorana, A., additional, Manni, P., additional, Piacentini, F., additional, Conte, P., additional, and Dominici, M., additional

Published
2016
Full Text
View/download PDF

29. Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Author

Omarini,Claudia, Palumbo,Patrizia, Pecchi,Annarita, Draisci,Stefano, Balduzzi,Sara, Nasso,Cecilia, Barbolini,Monica, Isca,Chrystel, Bocconi,Alessandro, Moscetti,Luca, Galetti,Silvia, Tazzioli,Giovanni, Torricelli,Pietro, Cascinu,Stefano, Piacentini,Federico, Omarini, C., Palumbo, P., Pecchi, A., Draisci, S., Balduzzi, S., Nasso, C., Barbolini, M., Isca, C., Bocconi, A., Moscetti, L., Galetti, S., Tazzioli, G., Torricelli, P., Cascinu, S., and Piacentini, F.

Subjects
Sarcopenia, Pathological complete response, Fat tissue, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, sarcopenia, BMI, breast cancer, Breast cancer, Cancer Management and Research, pathological complete response, fat tissue, BMI, fat tissue, sarcopenia, pathological complete response, breast cancer, Original Research
Abstract

Claudia Omarini,1 Patrizia Palumbo,2 Annarita Pecchi,3 Stefano Draisci,3 Sara Balduzzi,4 Cecilia Nasso,1 Monica Barbolini,1 Chrystel Isca,1 Alessandro Bocconi,1 Luca Moscetti,1 Silvia Galetti,5 Giovanni Tazzioli,6 Pietro Torricelli,3 Stefano Cascinu,1 Federico Piacentini1 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 2Division of Clinical Nutrition and Metabolism, Department of Specialist Medicines, University Hospital of Modena, Modena, Italy; 3Department of Radiology, University Hospital of Modena, Modena, Italy; 4Statistics Unit, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 5Division of Clinical Nutrition and Metabolism, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 6Department of General Surgery and Surgical Specialities, University Hospital of Modena, Modena, ItalyCorrespondence: Claudia OmariniDivision of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Via Del Pozzo 71, Modena 41122, ItalyTel +39 059 4222845Email claudia.omarini@gmail.comBackground: Fat tissue is strongly involved in BC tumorigenesis inducing insulin resistance, chronic inflammation and hormonal changes. Computed tomography (CT) imaging instead of body mass index (BMI) gives a reliable measure of skeletal muscle mass and body fat distribution. The impact of body composition parameters (BCPs) on chemosensitivity is still debated. We examined the associations between BCPs and tumor response to neoadjuvant chemotherapy (NC) in patients treated for operable breast cancer (BC).Methods: A retrospective review of BC patients treated with NC in Modena Cancer Center between 2005 and 2017 was performed. BCPs, such as subcutaneous fat area (SFA), visceral fat area (VFA), lumbar skeletal muscle index (LSMI) and liver-to-spleen (L/S) ratio were calculated by Advance workstation (General Electric), software ADW server 3.2 or 4.7. BMI and BCPs were correlated with pathological complete response (pCR) and survival outcomes.Results: 407 patients were included in the study: 55% with BMI < 25 and 45% with BMI ≥ 25. 137 of them had pre-treatment CT scan imagines. Overweight was significantly associated with postmenopausal status and older age. Hormonal receptor positive BC was more frequent in overweight patients (p

Published
2019

30. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

Author

P V Tomazic, M. Bewick, B. Samolinski, Torsten Zuberbier, Peter Hellings, M. T. Ventura, Olivier Vandenplas, Giorgio Walter Canonica, Gabrielle L. Onorato, T. Kostka, A. Todo Bom, L. Klimek, J. Just, F. Portejoie, Niels H. Chavannes, M. L. Kowalski, Bilun Gemicioglu, Ralph Mösges, Cristiana Stellato, K. C. Bergmann, T. Keil, Z. Gutter, S. Arnavielhe, David Price, Tari Haahtela, O. Spranger, Désirée Larenas-Linnemann, Massimo Triggiani, A. Yorgancioglu, Victoria Cardona, Jean-Louis Pépin, Adnan Custovic, Josep M. Antó, Nick A. Guldemond, Juan Carlos Ivancevich, B. Hellqvist-Dahl, I. Young, Robyn E O'Hehir, Benoit Pugin, H. Neffen, João O. Malva, P. Devillier, Cemal Cingi, R. Murray, J. Correia de Sousa, Erik Melén, N. Khaltaev, J. F. Fontaine, E Mathieu-Dupas, Antoine Magnan, M. Wickman, Nikolaos G. Papadopoulos, Aziz Sheikh, Leif Bjermer, G. De Vries, Edgardo Jares, F. E. R. Simons, Enrica Menditto, J. Millot-Keurinck, Sinthia Bosnic-Anticevich, Pascal Demoly, S. Palkonen, W. J. Fokkens, Jean Bousquet, S. Hun, Ronald Dahl, A. Zurkuhlen, D. Laune, A. Valero, M. Morais-Almeida, Ioana Agache, V. Kvedariene, Claus Bachert, I. Annesi-Maesano, Davide Caimmi, Milan Sova, Ana Maria Carriazo, João Fonseca, J. Bouchard, M. van Eerd, M. Barbolini, Joaquim Mullol, M. Illario, Inger Kull, Alvaro A. Cruz, E. De Manuel Keenoy, A. Bedbrook, Renaud Louis, Dermot Ryan, Piotr Kuna, Carsten Bindslev-Jensen, A. Senn, Guy Joos, Erkka Valovirta, A. Valiulis, Elaine Colgan, Paulo Augusto Moreira Camargos, G. Passalacqua, Filip Raciborski, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade de Lisboa (ULISBOA), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Service d'Allergologie pédiatrique [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Clinicum, Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, Universitat de Barcelona, Universidade do Minho, Bousquet, J., Onorato, G. L., Bachert, C., Barbolini, M., Bedbrook, A., Bjermer, L., De Sousa, J. Correia, Chavannes, N. H., Cruz, A. A., De Manuel Keenoy, E., Devillier, P., Fonseca, J., Hun, S., Kostka, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Larenas-Linnemann, D., Millot-Keurinck, J., Ryan, D., Samolinski, B., Sheikh, A., Yorgancioglu, A., Agache, I., Arnavielhe, S., Bewick, M., Annesi-Maesano, I., Anto, J. M., Bergmann, K. C., Bindslev-Jensen, C., Bosnic-Anticevich, S., Bouchard, J., Caimmi, D. P., Camargos, P., Canonica, G. W., Cardona, V., Carriazo, A. M., Cingi, C., Colgan, E., Custovic, A., Dahl, R., Demoly, P., De Vries, G., Fokkens, W. J., Fontaine, J. F., Gemicioǧlu, B., Guldemond, N., Gutter, Z., Haahtela, T., Hellqvist-Dahl, B., Jares, E., Joos, G., Just, J., Khaltaev, N., Keil, T., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Laune, D., Louis, R., Magnan, A., Malva, J., Mathieu-Dupas, E., Melén, E., Menditto, E., Morais-Almeida, M., Mösges, R., Mullol, J., Murray, R., Neffen, H., O'Hehir, R., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pépin, J. L., Portejoie, F., Price, D., Pugin, B., Raciborski, F., Simons, F. E. R., Sova, M., Spranger, O., Stellato, C., Todo Bom, A., Tomazic, P. V., Triggiani, M., Valero, A., Valovirta, E., Vandenplas, O., Valiulis, A., Van Eerd, M., Ventura, M. T., Wickman, M., Young, I., Zuberbier, T., Zurkuhlen, A., Senn, A., University of Manitoba, Public Health, and Health Services Management & Organisation (HSMO)

Subjects
Pediatrics, Al·lèrgia, ARIA, Asthma, CHRODIS, Good Practices, MASK, Rhinitis, Sunfrail, Immunology and Allergy, Immunology, Pulmonary and Respiratory Medicine, Allergy, CHRONIC, [SDV]Life Sciences [q-bio], Medicina Básica [Ciências Médicas], Alternative medicine, Review, ALLIANCE, WORLD-HEALTH-ORGANIZATION, RANDOMIZED, law.invention, GLOBAL ALLIANCE, 0302 clinical medicine, Randomized controlled trial, law, QUALITY-OF-LIFE, RESPIRATORY-DISEASES, Medicine and Health Sciences, GRADING QUALITY, 030212 general & internal medicine, Rhiniti, Rinitis, media_common, Checklist, CONTROLLED-TRIALS, 3. Good health, CHRONIC RESPIRATORY-DISEASES, Ciências Médicas::Medicina Básica, CLINICAL-PRACTICE GUIDELINES, Life Sciences & Biomedicine, GLOBAL, medicine.medical_specialty, Good Practice, Visual analogue scale, RANDOMIZED CONTROLLED-TRIALS, EUROPEAN INNOVATION PARTNERSHIP, MEDLINE, GOOGLE TRENDS, 03 medical and health sciences, Quality of life (healthcare), ECONOMIC BURDEN, medicine, media_common.cataloged_instance, ddc:610, European union, Science & Technology, business.industry, RC581-607, medicine.disease, 030228 respiratory system, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Immunologic diseases. Allergy, business
Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices., MACVIA-France., info:eu-repo/semantics/publishedVersion

Published
2017

31. Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 20-21, 2014, Lisbon July 2, 2015

Author

Karen Ritchie, Daniel Harman, Philippe-Jean Bousquet, Erik Melén, Pierre Senesse, Govert Joan Buijs, Antonio Cano, Claude Jeandel, Timo E. Strandberg, Marieke Van Beurden, Pascal Demoly, G. Moda, Raquel Santiago, Sylvie Arnavielhe, Marie-Eve Joel, Nicola Wilson, Eveline Wouters, Jacques Touchon, Martina O'Neill, Isabelle Momas, Karen Andersen Ranberg, D. Heve, Maddalena Illario, Christina Tischer, Jean Bousquet, Marcel Goldberg, Paola Bertone, Guido Iaccarino, Antoine Avignon, Rodolphe Bourret, Valeria Romano, Laura Calzà, Henriet A. Smit, Mirca Barbolini, David Kula, Jacques-Yves Pelissier, Mario Barbagallo, Bruno Vellas, Ann Scott, C. Robalo-Cordeiro, Gregoire Mercier, Mike Bewick, Bernard Combe, Holger Schulz, Sergio Bonini, P. Viriot-Durandal, Itziar Vergara, M. Nogues, Carol Brayne, João Apóstolo, Jacques Mercier, Vicente Traver-Salcedo, François Puisieux, Julia Coletta, Alessandro Blasimme, Olivier Krys, Niels H. Chavannes, John Farrell, Joël Ankri, Ana Maria Carriazo, Rafaelle Varraso, Marie Zins, Zdenec Gutter, José António Pereira da Silva, Bertrand Fougère, Frédéric Cuisinier, Bolesław Samoliński, Jacques Bringer, Theodore D. Cosco, Jordi Alonso, Ana Todo-Bom, Claudine Berr, Daniel Laune, Esteban De Manuel Keenoy, Judith Garcia-Aymerich, Anna Bedbrook, Anne Hendry, Richard Pengelly, Dagmar Poethig, João O. Malva, Thomas Keil, Sandra N. Slagter, Nick A. Guldemond, Pierre Matignon, Hubert Blain, Leocadio Rodríguez Mañas, Marek L. Kowalski, Susana Fernandez-Nocelo, Alfredo Cesario, Sandra Rebello, Federico Alonso, Catarina R. Oliveira, Dieter Maier, Jean-Pierre Michel, David Somekh, T. Camuzat, Julien Venne, Marc Criton, Jaime Correia de Sousa, Hassan Arshad, Anabella Mota Pinto, Valentina A. Andreeva, François Roubille, Yoav Ben-Shlomo, Asghar Zaidi, Elena Villalba-Mora, Emmanuelle Kesse-Guyot, Dirkje S. Postma, Carel Thijs, Jean-Marie Robine, Danielle Porta, George Crooks, Adrianna Nizinska, Jorge Suanzes, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Bone and Joint Research Group, University of Southampton Medical School, CHU Toulouse [Toulouse], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé, Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Social Medicine, University of Bristol [Bristol], Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-IFR76-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Electrical Engineering, Mathematics and Computer Science [Delft], Delft University of Technology (TU Delft), Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), F2ME, PSA Peugeot - Citroën (PSA), PSA Peugeot Citroën (PSA)-PSA Peugeot Citroën (PSA)-Laboratoire Pluridisciplinaire de Recherche en Ingénierie des Systèmes, Mécanique et Energétique (PRISME), Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges), Department of Epidemiology and Public Health, Imperial College London, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-École des hautes études en sciences sociales (EHESS), Département Ecologie, Physiologie et Ethologie (DEPE-IPHC), Institut Pluridisciplinaire Hubert Curien (IPHC), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS)-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw - Poland, Department of Epidemiology, Maastricht University [Maastricht]-School for Public Health and Primary Care (CAPHRI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Kyomed, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Geriatrics - Efficiency and Deficiency Laboratory, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Consiglio Nazionale delle Ricerche (CNR), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Public Health and Primary Care, University of Cambridge [UK] (CAM), Service d'endocrinologie, Departamento de Sistemas Informáticos y Computación [Valencia], Universitat Politècnica de València (UPV), Deputy Scientific Director, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Laboratoire de chimie biomoléculaire (LCB), Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-MAYOLI SPINDLER SA-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Bioingénierie et NanoSciences (LBN), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Laboratoire de Gérontechnologie [Hôpital La Grave-CHU de Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Gérontopôle, IMIM-Hospital del Mar, Generalitat de Catalunya, Département de Biostatistiques, Agence Régionale de Santé Languedoc Roussillon (ARS), Department of Medicine and Surgery, Università degli Studi di Salerno (UNISA)-RCCS 'Multimedia', Centre de gérontologie clinique, Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Lab-STICC_TB_CID_TOMS, Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA), Unité de Virologie clinique et fondamentale (UVCF), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Mécanismes adaptatifs : des organismes aux communautés (MAOAC), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Department of Pulmonary Medicine and Tuberculosis, University of Groningen [Groningen], Service de gériatrie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Département de nutrition et d'oncologie digestive, CRLCC Val d'Aurelle - Paul Lamarque, Institute of Epidemiology [Neuherberg] (EPI), German Research Center for Environmental Health - Helmholtz Center München (GmbH), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Bousquet, Jean, Malva, Joao, Nogues, Michel, Mañas, Leocadio Rodriguez, Vellas, Bruno, Farrell, J, Bewick, M, Kowalski, Ml, Strandberg, T, Alonso, J, Ranberg, Ka, Ankri, J, Barbagallo, M, Ben Shlomo, Y, Berr, C, Crooks, G, de Manuel Keenoy, E, Goldberg, M, Guldemond, N, Illario, Maddalena, Joel, Me, Kesse Guyot, E, Michel, Jp, Pengelly, R, Ritchie, K, Robine, Jm, Romano, V, Samolinski, B, Schulz, H, Thijs, C, Touchon, J, Zaidi, A, Apostolo, J, Alonso, F, Andreeva, V, Arnavielhe, S, Arshad, H, Avignon, A, Barbolini, M, Bedbrook, A, Bertone, P, Blain, H, Blasimme, A, Bonini, S, Bourret, R, Bousquet, Pj, Brayne, C, Bringer, J, Buijs, Gj, Calza, L, Camuzat, T, Cano, A, Carriazo, A, Cesario, A, Chavannes, N, Combe, B, Coletta, J, de Sousa, Jc, Cosco, T, Criton, M, Cuisinier, F, Demoly, P, Fernandez Nocelo, S, Fougère, B, Garcia Aymerich, J, Gutter, Z, Harman, D, Hendry, A, Hève, D, Iaccarino, G, Jeandel, C, Keil, T, Krys, O, Kula, D, Laune, D, Maier, D, Matignon, P, Melen, E, Mercier, G, Moda, G, Momas, I, Pinto, Am, Nizinska, A, Oliveira, C, O'Neill, M, Pelissier, Jy, Pereira da Silva, Ja, Poethig, D, Porta, D, Postma, D, Puisieux, F, Rebello, S, Robalo Cordeiro, C, Roubille, F, Santiago, R, Scott, A, Senesse, P, Slagter, S, Smit, Ha, Somekh, D, Suanzes, J, Tischer, C, Todo Bom, A, Traver Salcedo, V, Van Beurden, M, Varraso, R, Venne, J, Vergara, I, Villalba Mora, E, Viriot Durandal, P, Wilson, N, Wouters, E, Zins, M, Mercier, J., Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Cité (USPC)-Université Paris 13 (UP13)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut National de la Recherche Agronomique (INRA), Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Montpellier, Universidad Politécnica de Valencia, Centre National de la Recherche Scientifique (CNRS)-MAYOLI SPINDLER SA-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université Montpellier 2 - Sciences et Techniques (UM2), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Gérontopôle-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse], University of Salerno (UNISA)-RCCS 'Multimedia', Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Universidad Pública de Navarra [Espagne] (UPNA), Unité de Virologie clinique et fondamentale EA 4294, Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF)-Muséum national d'Histoire naturelle (MNHN), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Bousquet J, Malva J, Nogues M, Mañas LR, Vellas B, Farrell J, MACVIA Research Group [.., L. Calzà, ], Farrell, John, Bonini, Sergio, Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Muséum national d'Histoire naturelle (MNHN)-Collège de France (CdF)-Centre National de la Recherche Scientifique (CNRS), Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, and RS: CAPHRI - R5 - Optimising Patient Care

Subjects
Gerontology, Concept Formation, [SDV]Life Sciences [q-bio], Disability Evaluation, 0302 clinical medicine, SF-12, QUALITY-OF-LIFE, Surveys and Questionnaires, WHODAS 2.0, Medicine, 030212 general & internal medicine, VERSION, POPULATION, PSYCHOLOGICAL DISTRESS, SCALE, General Nursing, Nursing (all)2901 Nursing (miscellaneous), health care economics and organizations, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, education.field_of_study, Operational definition, Medicine (all), Health Policy, PHYSICAL-ACTIVITY QUESTIONNAIRE, PRIMARY-CARE, General Medicine, 3. Good health, Europe, General partnership, Scale (social sciences), Population, SELF-REPORT, VALIDATION, 03 medical and health sciences, Quality of life (healthcare), EQ-5D, Journal Article, Humans, OLDER-ADULTS, education, Geriatric Assessment, Health policy, Aged, business.industry, questionnaire, Active and healthy ageing, United States, Questionnaire, Quality of Life, The Conceptual Framework, Geriatrics and Gerontology, business, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

A core operational definition of active and healthy aging (AHA) is needed to conduct comparisons. A conceptual AHA framework proposed by the European Innovation Partnership on Active and Healthy Ageing Reference Site Network includes several items such as functioning (individual capability and underlying body systems), well-being, activities and participation, and diseases (including non-communicable diseases, frailty, mental and oral health disorders). The instruments proposed to assess the conceptual framework of AHA have common applicability and availability attributes. The approach includes core and optional domains/instruments depending on the needs and the questions. A major common domain is function, as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). WHODAS 2.0 can be used across all diseases and healthy individuals. It covers many of the AHA dimensions proposed by the Reference Site network. However, WHODAS 2.0 does not include all dimensions proposed for AHA assessment. The second common domain is health-related quality of life (HRQoL). A report of the AHA questionnaire in the form of a spider net has been proposed to facilitate usual comparisons across individuals and groups of interest. (C) 2015 Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2015

32. Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.

Author

Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, Gianni L, Maestri A, Minichillo S, Moscetti L, Mura A, Nicoletti SVL, Omarini C, Pagani R, Sarti S, Toss A, Zamagni C, Cuoghi Costantini R, Caggia F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, and Piacentini F

Subjects
Humans, Female, Middle Aged, Retrospective Studies, Adult, Aged, Treatment Outcome, Neoplasm Staging, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms metabolism, Trastuzumab administration & dosage, Trastuzumab adverse effects, Trastuzumab therapeutic use, Neoadjuvant Therapy methods, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Receptor, ErbB-2 metabolism
Abstract

Background: The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, without main safety concerns. The aim of NeoPowER trial is to evaluate safety and efficacy of P + H + CT in a real-world population., Methods: We retrospectively reviewed the medical records of stage II-III, HER2 + BC patients treated with NaT: who received P + H + CT (neopower group) in 5 Emilia Romagna institutions were compared with an historical group who received H + CT (control group). The primary endpoint was the safety, secondary endpoints were pCR rate, DRFS and OS and their correlation to NaT and other potential variables., Results: 260 patients were included, 48% received P + H + CT, of whom 44% was given anthraciclynes as part of CT, compared to 83% in the control group. The toxicity profile was similar, excluding diarrhea more frequent in the neopower group (20% vs. 9%). Three patients experienced significant reductions in left ventricular ejection fraction (LVEF), all receiving anthracyclines. The pCR rate was 46% (P + H + CT) and 40% (H + CT) (p = 0.39). The addition of P had statistically correlation with pCR only in the patients receiving anthra-free regimens (OR = 3.05,p = 0.047). Preoperative use of anthracyclines (OR = 1.81,p = 0.03) and duration of NaT (OR = 1.18,p = 0.02) were statistically related to pCR. 12/21 distant-relapse events and 14/17 deaths occurred in the control group. Patients who achieve pCR had a significant increase in DRFS (HR = 0.23,p = 0.009)., Conclusions: Adding neoadjuvant P to H and CT is safe. With the exception of diarrhea, rate of adverse events of grade > 2 did not differ between the two groups. P did not increase the cardiotoxicity when added to H + CT, nevertheless in our population all cardiac events occurred in patients who received anthracycline-containing regimens. Not statistically significant, higher pCR rate is achievable in patients receiving neoadjuvant P + H + CT. The study did not show a statistically significant correlation between the addition of P and long-term outcomes., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

33. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.

Author

Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, Omarini C, Toss A, Tamburrano F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, and Piacentini F

Subjects
Humans, Middle Aged, Female, Biomarkers, Tumor genetics, Retrospective Studies, High-Throughput Nucleotide Sequencing methods, Class I Phosphatidylinositol 3-Kinases genetics, Breast Neoplasms pathology
Abstract

Over the last two decades, the use of Next-Generation Sequencing (NGS) in medical oncology has increased the likelihood of identifying druggable mutations that may be potentially susceptible to targeted treatments. The European Society for Medical Oncology (ESMO) currently does not recommend the use of the NGS test to determine the therapeutic course of patients with metastatic breast cancer (mBC) in daily clinical practice. However, the aim of this work is to evaluate the potential contribution of the NGS test in selecting targeted therapies for patients with mBC. Data were retrospectively collected from 101 patients diagnosed with metastatic breast cancer and treated at the Modena Cancer Center between January 2015 and April 2022. A NGS test was performed on the tumor tissue of each patient at the Laboratory of Molecular Pathology of the University Hospital of Modena. This study analyzed the clinical-pathological characteristics and mutational profile of the population using NGS tests, with a focus on actionable mutations that could be targeted in advanced stages of clinical development. The indicator of this study was to quantify the actionable mutations that resulted in a change of cancer treatment. In total, 101 patients with metastatic breast cancer were analyzed, including 86 with luminal phenotype, 10 who were HER2-positive and 5 who were triple-negative. Median age was 52 years. NGS analysis was conducted on 47 samples of primary breast cancer, 52 on metastatic sites of disease and 2 on liquid biopsies. A total of 85 gene mutations were found. The most common mutations were identified in the PIK3CA (47%), FGFR (19%) and ERBB2 genes (12%), and to a lesser extent in other genes. Of the 61 patients with pathogenic mutations, 46 (75%) had at least one actionable mutation. Of these, nine received treatment with a molecular target drug: eight patients with a mutation of the PIK3CA gene were treated with alpelisib and fulvestrant; one patient with FGFR1/2 amplifications received TAS120. Median PFS for these patients was 3.8 months. The study results show that using the NGS test on cancer tissue of metastatic breast cancer could influence the therapeutic choices, considering the small sample size and limited follow-up. About 9% of the study population had their therapy modified based on the results of NGS. The growing number of detectable mutations and increased accessibility of the test may lead to a greater number of potential therapeutic implications for the NGS assay. Perspectives suggest that NGS analysis can be implemented in daily clinical practice, particularly in contexts where a Molecular Tumor Board (MTB) is active.

Published
2024
Full Text
View/download PDF

34. Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.

Author

D'Onofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, Cortesi L, Barbieri E, Canino F, Dominici M, and Moscetti L

Subjects
Humans, Female, Incidence, Aromatase Inhibitors adverse effects, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Breast Neoplasms drug therapy, Breast Neoplasms chemically induced, Thromboembolism chemically induced
Abstract

The adjuvant endocrine therapy (AET) of HR+ EBC has been changing in recent years. Aromatase inhibitors (AIs) as an upfront strategy (or as part of a switch strategy) have been added to the choice of Tamoxifen (T) alone. Increased TE risk is well known in T-treated patients, while AIs have shown a reduced TE rate. By adding the cyclin dependent kinase 4/6 inhibitors (CDK4/6) to AIs, an increase in TE rate has been shown. We conducted this meta-analysis to evaluate the impact of the AETs on TE incidence. Twelve randomized phase III trials were included. Four trials evaluated the upfront strategy, 6 assessed the switch and 2 the combination with a CDK4/6 inhibitor. The new AETs did not significantly modify or affect the rate of TE events (OR 0.847, 95% CI, 0.528-1.366, P = .489). The OR for CDK4/6 inhibitor plus ET vs. ET was 3.635 (P = .002). Excluding the CDK4/6 inhibitors, the overall OR for AIs vs. T was 0.628 (P < .001), while it was 0.781 (P = .151) for switching T vs. continuing T for 5 years, and 0.52 (P < .0001) for the upfront strategies with AIs. The AIs alone or plus CDK4/6 inhibitors did not affect the rate of TE events. AIs as an upfront strategy is the safest AET, associated with the lowest TE incidence. The switch strategy increases TE rate, whereas the addition of CDK4/6 to the standard AET was shown to significantly increase TE events. The results of the currently ongoing trials with CDK4/6 inhibitors will help obtain additional data to evaluate any differences among the different CDK4/6 inhibitors and clarify the weight of TE adverse events in the benefit/risk balance of this new adjuvant strategy., Competing Interests: Disclosure LM, AT have served as a member of an advisory board and received personal fees and travel grants from Pfizer and Eli Lilly. LC has served as consultant, member of an advisory board and received personal fees and travel grants from Pfizer CM and FP received personal fees and travel grants from Pfizer and Eli Lilly. EB and MB received travel grants from Eli Lilly. IS, RD, FC and MD did not declare competing interests., (Copyright © 2023 Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

35. Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.

Author

D'Onofrio R, Omarini C, Toss A, Sperduti I, Piacentini F, Barbolini M, Cortesi L, Barbieri E, Pettorelli E, Chiavelli C, Dominici M, and Moscetti L

Abstract

Background: Ovarian function suppression (OFS) and hormone therapy (HT) represent an adjuvant option in premenopausal hormone receptor-positive early breast cancer (HR+EBC). The SOFT-TEXT trials showed improved outcomes upon receiving aromatase inhibitors (AIs)/OFS., Methods: In order to estimate the magnitude of absolute improvements, we conducted a retrospective study applying composite risk (CR) to 237 premenopausal HR+EBC patients., Results: Overall, 119 of these received tamoxifen (T)/OFS and 118 received AIs/OFS. The median age was 45 years (ys). After a median follow up of 65 months, recurrence was 6.7% in T patients and 10.2% in AI ones. CR (cutoff: 2.67) and ET duration (five-year cutoff) was found to have a significant impact on DFS. Invasive disease-free survival (IDFS) at 5 ys amounted to 82.9% for a CR>2.67 and 95% with CR

Published
2023
Full Text
View/download PDF

36. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges.

Author

Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, Caggia F, Cerri S, Molinaro A, Dominici M, and Omarini C

Abstract

Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in several cases. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway mutations are frequent in BC (20-40%) and are significant causes of aggressive tumor behavior, as well as treatment resistance. Improving knowledge of the PI3K/AKT/mTOR pathway is an urgent need. This review aims to highlight the central role of PI3K-mTORC1/C2 mutations in the different BC subtypes, in terms of clinical outcomes and treatment efficacy. The broad base of knowledge in tumor biology is a key point for personalized BC therapy in the precision medicine era.

Published
2023
Full Text
View/download PDF

37. Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy.

Author

Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, Combi F, Cabitza E, Caggia F, Barbieri E, Barbolini M, Moscetti L, Omarini C, Piacentini F, Tazzioli G, Dominici M, and Cortesi L

Abstract

Introduction: Triple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for relapse in this subset of patients are poorly characterized. This study aimed to identify the predictive factors for relapse in TNBC patients without pCR after NACT., Methods: Women with TNBC treated with NACT from January 2008 to May 2020 at the Modena Cancer Center were included in the analysis. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of relapse., Results: We identified 142 patients with a median follow-up of 55 months. After NACT, 62 patients obtained pCR (43.9%). Young age at diagnosis (<50 years) and high Ki-67 (20%) were signi!cantly associated with pCR. Lack of pCR after NACT resulted in worse 5-year event-free survival (EFS) and overall survival (OS). Factors independently predicting EFS in patients without pCR were the presence of multifocal disease [hazard ratio (HR), 3.77; 95% CI, 1.45-9.61; p=0.005] and residual cancer burden (RCB) III (HR, 3.04; 95% CI, 1.09-9.9; p=0.04). Neither germline BRCA status nor HER2-low expression were associated with relapse., Discussion: These data can be used to stratify patients and potentially guide treatment decision-making, identifying appropriate candidates for treatment intensi!cation especially in neo-/adjuvant setting., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer EP declared a past co-editorship with one of the authors AT to the handling Editor., (Copyright © 2022 Toss, Venturelli, Civallero, Piombino, Domati, Ficarra, Combi, Cabitza, Caggia, Barbieri, Barbolini, Moscetti, Omarini, Piacentini, Tazzioli, Dominici and Cortesi.)

Published
2022
Full Text
View/download PDF

38. Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review.

Author

Canino F, Piacentini F, Omarini C, Toss A, Barbolini M, Vici P, Dominici M, and Moscetti L

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Everolimus therapeutic use, Female, Hormones therapeutic use, Humans, Lapatinib therapeutic use, Receptor, ErbB-2, Breast Neoplasms drug therapy, Breast Neoplasms pathology
Abstract

Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment for HR+/HER2- metastatic breast cancer (mBC). Primary or secondary endocrine resistance could develop; however validated biomarkers capable of predicting such a conditions are not available. Several studies have shown that HR+/HER2- mBC comprises five intrinsic subtypes. The purpose of this systematic review was to analyze the potential correlations between intrinsic subtype, efficacy of treatment, and patient outcome. Five papers that analyzed the intrinsic subtype with PAM50 assay in patients (pts) with HR+/HER2- mBC treated with ET (alone or in combination) within seven phase III clinical trials (EGF30008, BOLERO-2, PALOMA-2,3, MONALEESA-2,3,7) were identified. Non-luminal subtypes are more frequent in endocrine-resistant pts and in metastatic sites (vs. primary tumors), have less benefit from ET, and worse prognosis. Among these, HER2-enriched subtypes are similar to HER2+ tumors and benefit from the addition of anti-HER2 agents (lapatinib) and, for less clear reasons, of ribociclib (unconfirmed data for palbociclib and everolimus). Basal-like subtypes are similar to triple-negative tumors, making them more sensitive to chemotherapy. The intrinsic subtype is also not static but can vary over time with the evolution of the disease. Currently, the intrinsic subtype does not play a decisive role in the choice of treatment in clinical practice, but has potential prognostic and predictive value that should be further investigated.

Published
2022
Full Text
View/download PDF

39. T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.

Author

Omarini C, Piacentini F, Sperduti I, Cerma K, Barbolini M, Canino F, Nasso C, Isca C, Caggia F, Dominici M, and Moscetti L

Subjects
Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Receptor, ErbB-2 therapeutic use, Retrospective Studies, Trastuzumab therapeutic use, Breast Neoplasms pathology, Maytansine, Neoplasms, Second Primary
Abstract

Background: Current guidelines consider T-DM1 the standard 2 nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1 st line treatment. Despite this, there are no prospective studies supporting this sequence., Methods: We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1 st line TP in HER2 positive MBC patients. We used a random-effect model to find differences in the rate of 1-year progression free survival (PFS) between TP pre-treated population and the EMILIA phase III pivotal trial., Results: Seven studies were eligible. The meta-analysis showed a combined 1-year PFS risk difference for T-DM1 efficacy after TP in 2 nd or more lines of -0.122, with lower and upper limits of -0.253 and 0.010, respectively (p = 0.07), with low heterogeneity among studies (I 2 0.01%, p = 0.836). Considering the four studies on T-DM1 in 2 nd line setting, 1-year PFS risk was -0.034 (95% CI -0.207 - 0,139; p = 0.701) (I 2 0.01%, p = 0.91)., Conclusion: Overall, the efficacy of T-DM1 after TP seems to be similar to that previously reported in the EMILIA trial. In the second line setting, data are not mature enough to confirm T-DM1 efficacy in TP pre-treated population., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

40. The role of the Sunfrail tool in the screening of frailty and in integrated community-hospital care pathways: a retrospective observational study.

Author

Longobucco Y, Lauretani F, Gionti L, Tagliaferri S, Gobbens R, Kostka T, Palummeri E, Barbolini M, and Maggio M

Subjects
Aged, Frail Elderly, Geriatric Assessment, Hospitals, Humans, Retrospective Studies, Critical Pathways, Frailty diagnosis
Abstract

Background: One of the most problematic expression of ageing is frailty, and an approach based on its early identification is mandatory. The Sunfrail-tool (ST), a 9-item questionnaire, is a promising instrument for screening frailty., Aims: To assess the diagnostic accuracy and the construct validity between the ST and a Comprehensive Geriatric Assessment (CGA), composed by six tests representative of the bio-psycho-social model of frailty; To verify the discriminating power of five key-questions of the ST; To investigate the role of the ST in a clinical-pathway of falls' prevention., Methods: In this retrospective study, we enrolled 235 patients from the Frailty-Multimorbidity Lab of the University-Hospital of Parma. The STs' answers were obtained from the patient's clinical information. A patient was considered frail if at least one of the CGAs' tests resulted positive., Results: The ST was associated with the CGA's judgement with an Area Under the Curve of 0.691 (CI 95%: 0.591-0.791). Each CGA's test was associated with the ST total score. The five key-question showed a potential discriminating power in the CGA's tests of the corresponding domains. The fall-related question of the ST was significantly associated with the Short Physical Performance Battery total score (OR: 0.839, CI 95%: 0.766-0.918), a proxy of the risk of falling., Discussion: The results suggest that the ST can capture the complexity of frailty. The ST showed a good discriminating power, and it can guide a second-level assessment to key frailty domains and/or clinical pathways., Conclusions: The ST is a valid and easy-to-use instrument for the screening of frailty., (© 2021. The Author(s).)

Published
2022
Full Text
View/download PDF

41. Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.

Author

Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A, Piombino C, Moscetti L, Barbolini M, Maur M, Dominici M, and Omarini C

Abstract

MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.

Published
2021
Full Text
View/download PDF

42. Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report.

Author

Guaitoli G, Barbieri F, Barbolini M, Molinaro E, Emidio KD, Borghi V, Dominici M, and Bertolini F

Subjects
Adult, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung pathology, Humans, Immunotherapy, Lung Neoplasms complications, Lung Neoplasms pathology, Male, Nivolumab therapeutic use, Retreatment, Antibodies, Monoclonal, Humanized therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, HIV Infections complications, Immune Checkpoint Inhibitors therapeutic use, Lung Neoplasms drug therapy
Abstract

Immune checkpoint inhibitors (ICIs) changed management of non-small-cell lung cancer, but resistance usually develops. Today, at ICIs failure, chemotherapy is the treatment of choice, but the chance of immunotherapy rechallenge is appealing. Another challenging issue is whether it is safe to treat HIV-positive patients with ICIs: safety and efficacy of immunotherapy have been marginally considered in this subgroup. We report the case of a non-small-cell lung cancer patient treated by PD-1 inhibitors rechallenge despite his HIV-positivity, achieving good partial response with significant clinical benefit and without toxicities. Our experience underlines that HIV-positive patients can be treated similarly to HIV-negative individuals. HIV-positivity should be considered similar to other comorbidities, and not as a sufficient reason to preclude them the best available treatments.

Published
2021
Full Text
View/download PDF

43. Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy.

Author

Omarini C, Bettelli S, Manfredini S, Barbolini M, Isca C, Cortesi G, Maiorana A, Tazzioli G, Dominici M, and Piacentini F

Abstract

Introduction: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse prognosis, however, this group is heterogeneous. Nowadays limited data on predictive/prognostic biomarkers in patients with residual cancer disease are available., Methods: Using next-generation sequencing technology, we evaluated a panel of 21 cancer genes in a group of HER2 positive BC patients with residual disease after NACT. A control group of patients who achieved the pCR was selected too. The BC mutational profile was analyzed on both the tumor diagnostic biopsy and matched residual disease., Results: Overall, the detection rate of mutations was 79% in the No-pCR group versus 90% in the pCR cohort and 98% in the residual BC. The most mutated genes were TP53 and PIK3CA. No correlations between single gene mutations and survival outcomes were found. In no-pCR cohort, 52% of patients had different mutational profile after NACT, 69% of them had an increased in the number of mutated genes. Mutational profile changes from diagnostic biopsy to residual BC were a negative prognostic factor in term of relapse free survival: recurrence probability in different gene profile sub-group was 42% vs 0% in the same profile one (P = .019)., Conclusions: Treatment selective pressure on tumor cells due to NACT changed the gene mutational profile in more than half of BC patient with residual tumor disease. Treatment-induced gene mutations significantly increase the risk of relapse. Profiling primary and residual BC is a major step in order to further personalized adjuvant treatment strategy., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

44. Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib.

Author

Omarini C, Molinaro E, Barbolini M, Dominici M, and Piacentini F

Subjects
Aged, Female, Humans, Aminopyridines adverse effects, Benzimidazoles adverse effects, Breast Neoplasms drug therapy, IgA Vasculitis chemically induced
Abstract

Competing Interests: Declaration of competing interest I declare that we have no conflict of interest.

Published
2020
Full Text
View/download PDF

45. Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.

Author

Omarini C, Piacentini F, Sperduti I, Barbolini M, Isca C, Toss A, Cortesi L, Barbieri E, Dominici M, and Moscetti L

Subjects
Breast Neoplasms metabolism, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Female, Humans, Randomized Controlled Trials as Topic, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Practice Patterns, Physicians' statistics & numerical data, Protein Kinase Inhibitors therapeutic use, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
Abstract

Background: Elderly patients are underrepresented in clinical study where combined endocrine strategies were compared to endocrine therapy (ET) in hormone receptors positive, HER2 negative, metastatic breast cancer. The role of the new endocrine approaches in elderly women is still unclear., Methods: We performed a meta-analysis of first line phase II/III randomized trials on ET versus combined strategies considering clinical benefit and safety profile. Trials with hazard ratio (HR) for PFS in elderly patients were included., Results: Overall, the meta-analysis showed a PFS advantage for the experimental arms [HR 0.77, p 0.016] with a significant high/moderate heterogeneity [I2 65.46%, p 0.005]. For patients on CDK 4/6 inhibitors and ET, HR was 0.57 (p < 0.0001), with low heterogeneity [I2 0.0001%, p 0.96]. Hematological adverse events, as well as diarrhea with Abemaciclib, were significantly higher in elderly population., Conclusions: The magnitude of PFS benefit due to the combined strategies in elderly patients is similar to those reported in the overall clinical trial population. Adding CDK4/6 inhibitors to ET significantly prolongs PFS, even if toxicity profile have to be carefully considered. Future trials should be designed taking into account patients' age, geriatric assessment and comorbidity.

Published
2020
Full Text
View/download PDF

46. A Methodological Approach for Implementing an Integrated Multimorbidity Care Model: Results from the Pre-Implementation Stage of Joint Action CHRODIS-PLUS.

Author

Palmer K, Carfì A, Angioletti C, Di Paola A, Navickas R, Dambrauskas L, Jureviciene E, João Forjaz M, Rodriguez-Blazquez C, Prados-Torres A, Gimeno-Miguel A, Cano-Del Pozo M, Bestué-Cardiel M, Leiva-Fernández F, Poses Ferrer E, Carriazo AM, Lama C, Rodríguez-Acuña R, Cosano I, Bedoya-Belmonte JJ, Liseckiene I, Barbolini M, Txarramendieta J, de Manuel Keenoy E, Fullaondo A, Rijken M, and Onder G

Subjects
Adult, Aged, Aged, 80 and over, Delivery of Health Care, Integrated organization & administration, Female, Humans, Lithuania, Male, Middle Aged, Pilot Projects, Program Development, Rome, Spain, Chronic Disease therapy, Delivery of Health Care, Integrated methods, Multimorbidity, Patient Care Planning organization & administration
Abstract

Patients with multimorbidity (defined as the co-occurrence of multiple chronic diseases) frequently experience fragmented care, which increases the risk of negative outcomes. A recently proposed Integrated Multimorbidity Care Model aims to overcome many issues related to fragmented care. In the context of Joint Action CHRODIS-PLUS, an implementation methodology was developed for the care model, which is being piloted in five sites. We aim to (1) explain the methodology used to implement the care model and (2) describe how the pilot sites have adapted and applied the proposed methodology. The model is being implemented in Spain (Andalusia and Aragon), Lithuania (Vilnius and Kaunas), and Italy (Rome). Local implementation working groups at each site adapted the model to local needs, goals, and resources using the same methodological steps: (1) Scope analysis; (2) situation analysis-"strengths, weaknesses, opportunities, threats" (SWOT) analysis; (3) development and improvement of implementation methodology; and (4) final development of an action plan. This common implementation strategy shows how care models can be adapted according to local and regional specificities. Analysis of the common key outcome indicators at the post-implementation phase will help to demonstrate the clinical effectiveness, as well as highlight any difficulties in adapting a common Integrated Multimorbidity Care Model in different countries and clinical settings.

Published
2019
Full Text
View/download PDF

47. Proactive interception and care of Frailty and Multimorbidity in older persons: the experience of the European Innovation Partnership on Active and Healthy Ageing and the response of Parma Local Health Trust and Lab through European Projects.

Author

Longobucco Y, Benedetti C, Tagliaferri S, Angileri VV, Adorni E, Pessina M, Zerbinati L, Cicala L, Pelà G, Giacomini V, Barbolini M, Lauretani F, and Maggio MG

Subjects
Academic Medical Centers, Aged, Aged, 80 and over, European Union, Female, Frailty, Geriatric Assessment methods, Humans, Italy, Male, Multimorbidity, Physical Fitness physiology, Program Evaluation, Risk Assessment, Activities of Daily Living, Disability Evaluation, Health Planning organization & administration, Health Services for the Aged organization & administration, Healthy Aging physiology, Quality of Life
Abstract

According to the 2018 European Union Ageing Report, the demographic profile of the European population is projected to be older. Aging cannot be considered a homogeneous process, and only in certain cases is "successful", with maintained functional ability, which is determined by intrinsic capacity, the environment, and their interaction. When intrinsic capacity is lost, elders with chronic diseases develop frailty, a condition with high-risk of disability. Old-age dependency-ratio is projected to increase from 29.6% to 51.2% in the EU in 2070: thus, the need of new approaches targeting the prevention of disability. Numerous studies are conducted in the European Innovation Partnership on Active and Healthy Ageing and addressing identification, treatment, coordination and integration of care in frail older subjects. SUNFRAIL is aimed at developing a model, good practices and tools to improve the identification, prevention and care of frailty and management of multimorbidity. SPRINTT is testing the effectiveness of a multi-component treatment able to treat frailty and sarcopenia. VIGOUR, a project aimed at strengthening integrated-care in different contexts of European Countries, verifies enablers and obstacles encountered in the real world by these good practices. Through the creation of Parma-Lab and Frailty-Team in the Academic-Hospital of Parma combined with the contribution of Parma Health-Trust in the "Community Health-Centers", the Projects were translated into Health Services Arena. This response bridging European Studies and clinical practice, aims to early detecting and caring 75-year older citizens with frailty and multimorbidity, living in the community, not institutionalized and at risk of hospitalization and mobility ADL-disability.

Published
2019
Full Text
View/download PDF

48. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.

Author

Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, and Piacentini F

Subjects
Biopsy, Breast Neoplasms enzymology, Breast Neoplasms pathology, Cohort Studies, Female, Gene Expression Profiling, Humans, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases biosynthesis, Mitogen-Activated Protein Kinases genetics, Paraffin Embedding, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Receptors, Progesterone genetics, Retrospective Studies, Breast Neoplasms genetics, Breast Neoplasms metabolism, Receptor, ErbB-2 biosynthesis, Receptors, Estrogen biosynthesis, Receptors, Progesterone biosynthesis
Abstract

Purpose: Hormone receptors (HR) status in HER2 + breast cancer (BC) is a recognized stratification factor with relevant clinical implication. According to HR expression, HER2 + BC show different clinical characteristics, treatment sensitivity and prognosis. The interaction between HR and HER2 pathways remains incompletely understood., Methods: Thirty-four HER2 + BC were included: 18 tumors with HER2+/HR + and 16 with HER2+/HR-. The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer Pathway panel performed on FFPE BC biopsies., Results: Gene expression analysis identified 127 genes with significantly different expression between the two cohorts. 83% of these genes were overexpressed in HER2+/HR- cohort. Globally, 23% of them belonged to PI3K pathway (41 genes), 15% to Trascriptional regulation (26 genes) and 12% to MAPK (22 genes). Regarding pathway expression, PI3K, MAPK and NOTCH were significantly differently expressed between the two groups (p = 0.003, p = 0.0018 and p = 0.02, respectively), all of them were overexpressed in HER2+/HR- tumors., Conclusions: According to HR status, HER2 + tumors express different pathways profiles: the overexpression of PI3K, MAPK and NOTCH pathways in HER2+/HR- group could justify different survival outcomes and treatment sensitivity. The identification of tumor driver pathways may be a useful instrument for individualized pathway-directed therapies. Further clinical implications are warranted.

Published
2019
Full Text
View/download PDF

49. The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Author

Bousquet J, Illario M, Farrell J, Batey N, Carriazo AM, Malva J, Hajjam J, Colgan E, Guldemond N, Perälä-Heape M, Onorato GL, Bedbrook A, Leonardini L, Stroetman V, Birov S, Abreu C, Abrunhosa A, Agrimi A, Alalääkkölä T, Allegretti N, Alonso-Trujillo F, Álvarez-Benito M, Angioli S, Apóstolo J, Armitage G, Arnavielhe S, Baena-ParejoI M, Bamidis PD, Balenović A, Barbolini M, Baroni I, Blain H, Bernard PL, Bersani M, Berti E, Bogatyrchuk L, Bourret R, Brehm J, Brussino L, Buhr D, Bultje D, Cabeza E, Cano A, De Capitani C, Carantoña E, Cardoso A, Coll Clavero JI, Combe B, Conforti D, Coppola L, Corti F, Coscioni E, Costa E, Crooks G, Cunha A, Daien C, Dantas, Darpón Sierra J, Davoli M, Dedeu Baraldes A, De Luca V, De Nardi L, Di Ciano M, Dozet A, Ekinci B, Erve S, Espinoza Almendro JM, Fait A, Fensli R, Fernandez Nocelo S, Gálvez-Daza P, Gámez-Payá J, García Sáez M, Garcia Sanchez I, Gemicioğlu B, Goetzke W, Goossens E, Geurdens M, Gütter Z, Hansen H, Hartman S, Hegendörfer G, Heikka H, Henderson D, Héran D, Hirvonen S, Iaccarino G, Jansson N, Kallasvaara H, Kalyoncu F, Kirchmayer U, Kokko JA, Korpelainen J, Kostka T, Kuna P, Lajarín Ortega T, Lama CM, Laune D, Lauri D, Ledroit V, Levato G, Lewis L, Liotta G, Lundgren L, Lupiañez-Villanueva F, Mc Garry P, Maggio M, Manuel de Keenoy E, Martinez C, Martínez-Domene M, Martínez-Lozano Aranaga B, Massimilliano M, Maurizio A, Mayora O, Melle C, Mendez-Zorilla A, Mengon H, Mercier G, Mercier J, Meyer I, Millet Pi-Figueras A, Mitsias P, Molloy DW, Monti R, Moro ML, Muranko H, Nalin M, Nobili A, Noguès M, O'Caoimh R, Pais S, Papini D, Parkkila P, Pattichis C, Pavlickova A, Peiponen A, Pereira S, Pépin JL, Piera Jiménez J, Portheine P, Potel L, Pozzi AC, Quiñonez P, Ramirez Lauritsen X, Ramos MJ, Rännäli-Kontturi A, Risino A, Robalo-Cordeiro C, Rolla G, Roller R, Romano M, Romano V, Ruiz-Fernández J, Saccavini C, Sachinopoulou A, Sánchez Rubio MJ, Santos L, Scalvini S, Scopetani E, Smedberg D, Solana-Lara R, Sołtysik B, Sorlini M, Stericker S, Stramba Badiale M, Taillieu I, Tervahauta M, Teixeira A, Tikanmäki H, Todo-Bom A, Tooley A, Tuulonen A, Tziraki C, Ussai S, Van der Veen S, Venchiarutti A, Verdoy-Berastegi D, Verissimo M, Visconti L, Vollenbroek-Hutten M, Weinzerl K, Wozniak L, Yorgancıoğlu A, Zavagli V, and Zurkuhlen AJ

Abstract

Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs.

Published
2019

50. Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.

Author

Omarini C, Filieri ME, Bettelli S, Manfredini S, Kaleci S, Caprera C, Nasso C, Barbolini M, Guaitoli G, Moscetti L, Maiorana A, Conte PF, Cascinu S, and Piacentini F

Subjects
Aged, Breast Neoplasms drug therapy, Breast Neoplasms pathology, DNA Mutational Analysis, Female, Genes, Neoplasm genetics, Humans, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Retrospective Studies, Sirolimus, Androstadienes therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms genetics, Everolimus therapeutic use, Phosphatidylinositol 3-Kinases metabolism
Abstract

Background: Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of everolimus efficacy have been investigated in primary breast cancer tissue without finding univocal results. The goal of this study was to investigate the mutational burden in the metastatic site of endocrine-resistant tumors treated with everolimus plus exemestane., Patients and Methods: Mass Array Sequenom platform was used to analyse genetic status of 18 cancer-related genes in 25 archival tumor specimens from metastatic lesions and available primary matched breast cancer tissue of patients treated with everolimus and exemestane for advanced disease. An exploratory analysis of everolimus efficacy in terms of progression free survival benefit and single gene mutation was carried out., Results: The overall detection rate of mutation was 30% and 38% from metastatic and primary breast cancer samples, respectively. AKT1 E17K was the most frequent mutated gene. No primary breast cancer and matched relapse maintained the same mutation profile. Considering molecular pathways, the most of the genes belong to PI3K pathway (AKT1 E17K , PI3KCA E545K , and KIT G565R,S709F ). In patients with detected mutations in breast and/or recurrence tissue the median PFS was 5,6 months while in the subgroup of patients with no mutations the median PFS was 7,5 months., Conclusions: The mutational status of breast cancer recurrence allows the identification of some genes potentially correlating tumor response/resistance to everolimus. The most frequently mutated genes were involved in the PI3K/AKT/mTOR pathway highlighting that the deregulation of this pathway in the relapse plays a crucial role in the mechanisms of everolimus resistance/sensitivity. Owing to the small sample size and the retrospective nature of the study, these correlations need to be validated in a large prospective study.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results